A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma

Name: A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma
License: Public Domain

Sun Yat-sen University

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

hepatocellular carcinoma (hcc), second line treatment

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 158195
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.